Samples

Revenue segments as reported by the company.

Test revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Change in fair value of contingent consideration

Asset impairment

Restructuring

Gain on sale of RUO kit assets

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Invitae

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Invitae reports strong Q4 earnings, eyes growth amid challenges

Invitae's Q4 2022 performance showcased revenue growth, improved margins, and reduced cash burn, positioning the company for sustainable growth.
Strategic investments in key growth areas and a focus on customer experience and profitability underpin Invitae's vision for the future.
Addressing supply chain challenges while seizing opportunities for expansion and innovation will be critical for Invitae's continued success.

Invitae (NVTA) reports robust Q1 earnings and advances in PCM technology

Invitae's Q1 2023 earnings call highlighted strong financial performance, operational strengths, and strategic advancements in PCM technology.
The company's focus on growth, margin expansion, and debt management underscores a path towards sustainable profitability.
While facing challenges in reimbursement dynamics and competitive landscape, Invitae remains poised to capitalize on growth opportunities.

Invitae reports Q2 revenue growth, adjusts guidance amid challenges

Invitae shows progress towards profitability with improved margins and reduced cash burn.
Challenges in hereditary cancer revenue and PGX exit impact revenue guidance.
Focus on expanding customer base, improving reimbursement, and reducing cash burn.
Continuous investment in products for future growth and competitiveness.

Invitae reports robust Q3 earnings, addresses financial concerns proactively

Invitae's Q3 2023 performance was strong, with revenue growth and margin expansion. The company faces challenges in capital structure and insurance payments but is actively addressing them. Opportunities lie in revenue growth, operational improvements, and expanding genetic testing services.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Invitae is a genetic information company whose mission is to bring genetic information into routine medical practice to improve the quality of healthcare for billions of people.  Specializing in genetic diagnostics for hereditary disorders, Invitae is aggregating the world’s genetic tests into a single service with better quality, faster turnaround time, and a lower price than most single-gene diagnostic tests today.  What’s our plan? It takes three steps:  --Make genetic testing more affordable and accessible than ever before. --Build a secure and trusted genome management infrastructure. --Design a new global community for sharing genetic information to advance science and medicine.  Today, we are reinventing genetic testing by lowering the barriers for clinicians and patients to obtain diagnostic genetic information. Together we can improve healthcare for billions of people.

SAN FRANCISCO , April 26, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce First Quarter 2023 Financial Results on Tuesday, May 9, 2023

Invitae grew revenue in 2022 by 12.1%. It had $1.3 billion in net losses last year.

Why Shares of Invitae Soared on Friday

Invitae (NYSE: NVTA), a leading medical genetics company, today published its 2023 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and

Invitae Publishes Annual Environmental, Social and Governance (ESG) Report

– The partnership will harness genetic and clinical data from millions of patients tested at Invitae and Deerfield's expertise in drug discovery to address high unmet needs among rare disease patients – SAN FRANCISCO , March 22, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, and Deerfield Management Company , a healthcare investment firm, today announced a partnership to advance genetics-based drug discovery and development in rare disease. The partnership will leverage genetics and clinical data from millions of patients and Deerfield's broad drug discovery and development expertise.

Invitae and Deerfield Management Partner to Create Novel Therapeutics for Rare Diseases

– Collaboration will simplify providers' and patients' access to discrete test results that can inform more precise, personalized medicine – SAN FRANCISCO , March 21, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, today announced its partnership with Epic, an industry-leading healthcare software company.  Through Aura, Epic's specialty diagnostics suite, Invitae will streamline interactions with provider organizations in the Epic community, making test result information available in providers' usual workflows so that it's easier to use genetic insights to inform treatment decisions.

Invitae Announces Partnership with Epic to Streamline Genetic Testing

– Expert in the field of gastrointestinal cancer and precision oncology to lead Invitae's medical oncology team with a particular focus on somatic testing development –  – Invitae reports inducement grant under NYSE Rule 303A.08 –  SAN FRANCISCO , March 16, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced the appointment of W. Michael Korn, M.D.

Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology

– New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing – SAN FRANCISCO , March 15, 2023 /PRNewswire/ -- Invitae  (NYSE: NVTA), a leading medical genetics company, today announced seven studies, including one oral presentation and six posters, to be presented at the 2023 American Clinical Genetics Meeting held in Salt Lake City from March 14-18, 2023. The research reinforces the importance of universal genetic testing for patients with cancer, with much of the data highlighting the need for increased representation in clinical genetic testing data across racial, ethnic and ancestry groups that have long been underrepresented in genetic studies and databases.

Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing

Archer Aviation

Amyris

BigBear.ai Holdings

Desktop Metal

Eos Energy Enterprises

Farfetch

Penny stocks with unusual options activity today. The post 7 Penny Stocks To Watch Under $5 With Unusual Options Action appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

7 Penny Stocks To Watch Under $5 With Unusual Options Action

Unusual options activity put these penny stocks on watch lists this week.

4 Penny Stocks To Buy For Under $5 With Unusual Options Action

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to address its convertible debt deal, fully repaid its senior secured term loan, and reduced its ongoing cash burn to $77 million for the quarter.

Invitae's Battle To Reignite Revenue Growth And Overcome Financial Challenges

Invitae Corporation (NYSE:NVTA ) TD Cowen 43rd Annual Health Care Conference Transcript March 6, 2023 1:30 PM ET Executives Ken Knight - President and CEO Roxi Wen - Chief Financial Officer Analysts Dan Brennan - Cowen and Company Dan Brennan Yes. Thank you.

Invitae Corporation (NVTA) Management Presents at TD Cowen 43rd Annual Health Care Conference (Transcript)

– Blue Shield of California has over 3 million covered members in CA – SAN FRANCISCO , March 6, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that its Personalized Cancer Monitoring (PCM™) assay, which helps detect minimal residual disease (MRD) in patients, has obtained its first commercial coverage in all solid tumors by Blue Shield of California. The policy, effective as of March 1, 2023, considers the test medically necessary for patients with stage I-IV cancer after surgical intervention for adjuvant or targeted therapy and/or monitoring for relapse or progression.

Invitae's PCM Assay for Minimal Residual Disease Receives its First Commercial Coverage

SAN FRANCISCO , March 1, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that Ken Knight, president and chief executive officer, will participate in a fireside chat at the TD Cowen 43rd Annual Health Care Conference on Monday, March 6, at 1:30 p.m. Eastern. A live audio webcast of the fireside chat may be accessed by visiting the investors section of the company's website at ir.invitae.com.

Invitae to Present at the TD Cowen 43rd Annual Health Care Conference

Invitae (NVTA) delivered earnings and revenue surprises of 38.18% and 1.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Invitae (NVTA) Reports Q4 Loss, Tops Revenue Estimates

Invitae Corporation (NYSE:NVTA ) Q4 2022 Earnings Conference Call February 28, 2023 4:30 PM ET Company Participants Hoki Luk - Investor Relations Ken Knight - President and Chief Executive Officer Roxi Wen - Chief Financial Officer Conference Call Participants Gabriella Gabel - Morgan Stanley Dustin Scaringe – William Blair Jeffrey Cohen - Ladenburg Operator Hello, everybody, and welcome to the Invitae Fourth Quarter 2020 Financial Results Conference Call. My name is Sam, and I will be coordinating your call today.

Invitae Corporation (NVTA) Q4 2022 Earnings Call Transcript

– In a transaction led by Deerfield Management, the Company effectively addresses ~96% of its 2024 convertible debt obligations – – Participating holders to exchange 90% of their existing 2024 notes for new notes due in 2028 and equitize 10% of their holdings; Certain investors will also provide an additional $30 million of capital – – The Company will discuss this announcement during its fourth quarter and full year 2022 earnings call at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Announces Convertible Notes and Share Exchange and New Convertible Notes Issuance

– Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) –  – Repaid its 2024 senior secured term loan in full, improving its balance sheet – – Company maintains cash runway through the end of 2024 – – Annual revenue grew by 12.1%; Continued to improve on key financial metrics – – Major initiatives under strategic realignment largely completed – – Guiding to low double digit pro forma revenue growth and continued expansion of non-GAAP gross margin in 2023, decreasing cash burn by over 45% from 2022 – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m.

Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates

It doesn't look good, but the company isn't doomed just yet.

Down 78% in 1 Year, Is There Any Hope Left for Invitae?

SAN FRANCISCO , Feb. 14, 2023 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, February 28, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Invitae to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023

Ally Financial

Black Hills

Shake Shack

T2 Biosystems

World Acceptance

In order for a free market to operate, investors must be willing to participate in both sides of the transaction, which brings us to the topic of the stocks to short this week. If you're feeling optimistic about the pessimistic trajectory of embattled enterprises, this list may be for you.

The 7 Best Stocks to Short This Week

The stock has been off to a red-hot start in 2023.

Is It Too Late to Buy Invitae Stock?

The company's $350 million question mark could overshadow recent progress.

Invitae Stock: Approach With Caution

– Brings invaluable expertise in leading, operating and scaling global businesses throughout his career in aerospace, transportation and integrated solutions – SAN FRANCISCO , Jan. 30, 2023 /PRNewswire/ --  Invitae  (NYSE: NVTA), a leading medical genetics company, has announced that aerospace, transportation and industrial supplies veteran William H. Osborne has been appointed to its board of directors and will also serve on its audit committee, effective January 26, 2023.

Invitae Appoints William H. Osborne to its Board of Directors

ARK Innovation ETF

Coinbase

CRISPR Therapeutics

DraftKings

Exact Sciences

Pacific Biosciences of California

Roblox

Roku

10X Genomics

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

Invitae Corporation (NYSE:NVTA ) 41st Annual JPMorgan Healthcare Conference January 11, 2023 12:00 PM ET Company Participants Kenneth Knight - Chief Executive Officer Dr. Bob Nussbaum - Chief Medical Officer Roxi Wen - Chief Financial Officer Dr. Valerie Montgomery Rice - President and CEO, Morehouse School of Medicine Conference Call Participants Julia Qin - JPMorgan Chase Julia Qin All right. Good morning, everyone.

News for Invitae Stock (NVTA)